Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 1/20 | 0.36 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.32 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23594252 | 0.91 | ACHE (0.35) | ACHECHRM5ADRA2C | |
| SCHEMBL24927414 | 0.87 | ACHE (0.41) | ACHECHRM5ADRA2C | |
| SCHEMBL23594023 | 0.83 | ACHE (0.37) | ACHECHRM5ADRA2C | |
| SCHEMBL25951479 | 0.82 | — | — | |
| SCHEMBL24926124 | 0.82 | ACHE (0.34) | ACHECHRM5ADRA2C | |
| SCHEMBL25936897 | 0.82 | ACHE (0.31) | ACHE | |
| SCHEMBL21933625 | 0.80 | ACHE (0.32) | ACHECHRM5ADRA2C | |
| SCHEMBL26419154 | 0.80 | CHRM5 (0.41) | ACHECHRM5ADRA2C | |
| SCHEMBL26419153 | 0.80 | CHRM5 (0.46) | ACHECHRM5ADRA2C | |
| SCHEMBL23594611 | 0.80 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230227471-A1 | BIFUNCTIONAL COMPOUNDS FOR DEGRADING BTK VIA UBIQUITIN PROTEOSOME PATHWAY | NURIX THERAPEUTICS, INC. | 2023-07-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230227471-A1 | BIFUNCTIONAL COMPOUNDS FOR DEGRADING BTK VIA UBIQUITIN PROTEOSOME PATHWAY | BTK, CBL, XIAP | ACHE 3887/4885CHRM5 4847/4885ADRA2C 4544/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.